{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:43:30Z","timestamp":1792226610048,"version":"4.4.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U19AI123862-01"],"award-info":[{"award-number":["1U19AI123862-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03AI131066"],"award-info":[{"award-number":["R03AI131066"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R21CA209940-01A1"],"award-info":[{"award-number":["1R21CA209940-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0363"],"award-info":[{"award-number":["W81XWH-16-1-0363"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["2017\/1633"],"award-info":[{"award-number":["2017\/1633"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1053\/j.gastro.2018.10.024","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T15:31:39Z","timestamp":1539790299000},"page":"431-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges"],"prefix":"10.1053","volume":"156","author":[{"given":"Thomas F.","family":"Baumert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2018.10.024_bib2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","author":"Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/apt.14204","article-title":"Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-na\u00efve, genotype 1 hepatitis C infected patients","volume":"46","author":"Curry","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.10.024_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib8","doi-asserted-by":"crossref","unstructured":"Berg T, Naumann U, Stoehr A, et\u00a0al. First real-world data on safety and effectiveness of glecaprevir\/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: data from the German Hepatitis C-Registry. Abstract GS-007. Presented at: 53rd Annual Meeting of the European Association for the Study of the Liver; April 13, 2018; Paris France.","DOI":"10.1016\/S0168-8278(18)30290-3"},{"key":"10.1053\/j.gastro.2018.10.024_bib9","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, et\u00a0al. Real-life effectiveness and safety of glecaprevir\/pibrentasvir among 723 Italian patients with chronic hepatitis C: the Navigator-II study. Abstract GS-013. Presented at: 53rd Annual Meeting of the European Association for the Study of the Liver; April 13, 2018; Paris France.","DOI":"10.1016\/S0168-8278(18)30351-9"},{"key":"10.1053\/j.gastro.2018.10.024_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"Kohli","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2018.10.024_bib11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.7326\/M15-0642","article-title":"Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial","volume":"163","author":"Kohli","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/civ897","article-title":"Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease","volume":"62","author":"Kattakuzhy","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/liv.12861","article-title":"Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy","volume":"35","author":"Al Marzooqi","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2016.05.021","article-title":"Efficacy of the\u00a0combination of sofosbuvir, velpatasvir, and the NS3\/4A protease inhibitor GS-9857 in treatment-na\u00efve or previously treated patients with hepatitis C virus genotype 1 or 3 infections","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: a randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/liv.13335","article-title":"Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)","volume":"37","author":"Sulkowski","year":"2017","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy\u2014predicting effects of treatment","volume":"12","author":"Perelson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib18","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1038\/s41598-017-09776-z","article-title":"The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?","volume":"7","author":"Nguyen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2018.10.024_bib19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/liv.13165","article-title":"On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir","volume":"36","author":"Kowdley","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/jvh.12731","article-title":"Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C","volume":"24","author":"Johnson","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.10.024_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","article-title":"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study","volume":"1","author":"Lau","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jceh.2017.08.003","article-title":"Chronic hepatitis C: do generics work as well as branded drugs?","volume":"7","author":"Premkumar","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12664-017-0763-3","article-title":"Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1053\/j.gastro.2018.10.024_bib24","doi-asserted-by":"crossref","first-page":"7579689","DOI":"10.1155\/2018\/7579689","article-title":"Role of direct antiviral agents in treatment of chronic hepatitis C infection in renal transplant recipients","volume":"2018","author":"Sharma","year":"2018","journal-title":"J Transplant"},{"key":"10.1053\/j.gastro.2018.10.024_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination\u2014a path to global elimination of hepatitis C","volume":"67","author":"Lazarus","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.10.024_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13668","article-title":"Is global elimination of HCV realistic?","volume":"38","author":"Calvaruso","year":"2018","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib27","doi-asserted-by":"crossref","first-page":"e101554","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis","volume":"9","author":"Yehia","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.10.024_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jhep.2016.04.012","article-title":"Disparities in hepatitis C testing in U.S. veterans born 1945-1965","volume":"65","author":"Sarkar","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib29","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.amepre.2017.01.033","article-title":"Recent hepatitis C virus testing patterns among baby boomers","volume":"53","author":"Jemal","year":"2017","journal-title":"Am J Prev Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib30","doi-asserted-by":"crossref","first-page":"ofw211","DOI":"10.1093\/ofid\/ofw211","article-title":"Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency department","volume":"3","author":"Franco","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib31","author":"LaMattina"},{"key":"10.1053\/j.gastro.2018.10.024_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","article-title":"Disparities in absolute denial of modern hepatitis C therapy by type of insurance","volume":"14","author":"Lo Re","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ajg.2017.87","article-title":"Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C","volume":"112","author":"Ooka","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2018.10.024_bib35","doi-asserted-by":"crossref","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib36","doi-asserted-by":"crossref","first-page":"j5054","DOI":"10.1136\/bmj.j5054","article-title":"MSF pushes down price of generic hepatitis C drugs to new low level","volume":"359","author":"Wise","year":"2017","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2018.10.024_bib37","series-title":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low and middle income countries, March 2018. Licence: CC BY-NC-SA 30 IGO","year":"2018"},{"key":"10.1053\/j.gastro.2018.10.024_bib38","first-page":"128","article-title":"Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals","volume":"4","author":"Hill","year":"2018","journal-title":"J\u00a0Virus Erad"},{"key":"10.1053\/j.gastro.2018.10.024_bib39","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.27641","article-title":"Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus","volume":"61","author":"van de Ven","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jvh.12870","article-title":"Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection","volume":"25","author":"Gupta","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.10.024_bib41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","article-title":"Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study","volume":"66","author":"Zeng","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1053\/j.gastro.2018.10.024_bib42","doi-asserted-by":"crossref","first-page":"e45788","DOI":"10.5812\/hepatmon.45788","article-title":"Generic direct acting antiviral treatment: the first step towards elimination of hepatitis C in Iran","volume":"17","author":"Hajarizadeh","year":"2017","journal-title":"Hepat Mon"},{"key":"10.1053\/j.gastro.2018.10.024_bib43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2017.05.011","article-title":"Response tailored protocol versus the fixed 12 weeks course of\u00a0dual sofosbuvir\/daclatasvir treatment in Egyptian patients with chronic hepatitis C genotype-4 infection: a\u00a0randomized, open-label, non-inferiority trial","volume":"21","author":"Yakoot","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1053\/j.gastro.2018.10.024_bib44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jmv.25033","article-title":"Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study","volume":"90","author":"Marciano","year":"2018","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.10.024_bib45","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/liv.13863","article-title":"Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease","volume":"38","author":"Sharma","year":"2018","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jceh.2017.08.002","article-title":"Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major","volume":"7","author":"Nagral","year":"2017","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib47","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/apt.14647","article-title":"Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection","volume":"47","author":"Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.10.024_bib48","unstructured":"Freeman J, Kjwairakpam G, Dragunova J, et\u00a0al. 94% SVR with parallel imported generic direct acting antiviral treatment for hepatitis C. Abstract PS-097. Presented at: 52nd Annual Meeting of the European Association for the Study of the Liver; Amsterdam, The Netherlands; April 19\u201323,\u00a02017."},{"key":"10.1053\/j.gastro.2018.10.024_bib49","first-page":"200","article-title":"High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C","volume":"3","author":"Hill","year":"2017","journal-title":"J\u00a0Virus Erad"},{"key":"10.1053\/j.gastro.2018.10.024_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/apt.14428","article-title":"Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt","volume":"47","author":"Omar","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.10.024_bib51","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jhep.2018.01.021","article-title":"The Egyptian hepatitis C programme: a model of HCV treatment intervention?","volume":"68","author":"Lemoine","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/j.gastro.2014.05.010","article-title":"Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man","volume":"147","author":"Franco","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib56","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2018.06.021","article-title":"Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV\/HCV-coinfected MSM with risk of onward transmission","volume":"69","author":"Newsum","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jhep.2017.09.008","article-title":"Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?","volume":"68","author":"Di Maio","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib61","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jhep.2017.06.035","article-title":"Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries","volume":"67","author":"Silva Filipe A da","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib62","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","article-title":"Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection","volume":"64","author":"Abergel","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib63","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S2468-1253(17)30257-1","article-title":"Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination?","volume":"2","author":"Niebel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib64","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep4.1060","article-title":"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment","volume":"1","author":"Gane","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2018.10.024_bib65","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib66","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In\u00a0vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib68","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib69","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib70","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.gastro.2016.08.043","article-title":"Hepatitis C drugs: is next generation the last generation?","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib72","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/TP.0000000000001606","article-title":"Immune reconstitution after HCV clearance with direct antiviral agents: potential consequences for patients with HCC?","volume":"101","author":"Werner","year":"2017","journal-title":"Transplantation"},{"key":"10.1053\/j.gastro.2018.10.024_bib73","doi-asserted-by":"crossref","first-page":"e0186213","DOI":"10.1371\/journal.pone.0186213","article-title":"Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy","volume":"12","author":"Burchill","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.10.024_bib74","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/hep.29921","article-title":"Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during DAA therapy","volume":"68","author":"Alao","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib75","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/liv.13360","article-title":"Overcoming the resistance to resistance testing: collecting the data","volume":"37","author":"Doyle","year":"2017","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib76","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep4.1050","article-title":"Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review","volume":"1","author":"Bartlett","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2018.10.024_bib77","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1093\/jac\/dkx302","article-title":"Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study","volume":"72","author":"Cento","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2018.10.024_bib78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"73","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1053\/j.gastro.2018.10.024_bib79","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1126\/science.1259210","article-title":"Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase","volume":"347","author":"Appleby","year":"2015","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.10.024_bib80","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","article-title":"Management of direct-acting antiviral agent failures","volume":"63","author":"Buti","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib81","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib82","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib83","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib84","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib85","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2018.10.024_bib86","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/jvh.12932","article-title":"Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures","volume":"25","author":"Jeong","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.10.024_bib87","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE study","volume":"66","author":"L\u00e9dinghen V de","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib88","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix214","article-title":"Sofosbuvir-daclatasvir-simeprevir plus ribavirin in direct-acting antiviral-experienced patients with hepatitis C","volume":"64","author":"H\u00e9zode","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib89","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10620-018-5005-8","article-title":"Retreatment efficacy of sofosbuvir\/ombitasvir\/paritaprevir\/ritonavir\u2009+\u2009ribavirin for hepatitis C virus genotype 4 patients","volume":"63","author":"Abdel-Moneim","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2018.10.024_bib90","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis c virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.10.024_bib91","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2015.12.021","article-title":"Addressing the next challenges: a summary of the 22nd international symposium on hepatitis C virus and related viruses","volume":"64","author":"Baumert","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib92","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17512433.2017.1313111","article-title":"Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV","volume":"10","author":"Hayes","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1053\/j.gastro.2018.10.024_bib93","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1473-3099(16)30005-6","article-title":"Access to treatment for hepatitis C virus infection: time to put patients first","volume":"16","author":"Edlin","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib94","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib95","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection-drug users\u2014a hidden danger of the opioid epidemic","volume":"378","author":"Liang","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib96","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","author":"Smith","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib97","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.10.024_bib98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/liv.13626","article-title":"Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in \u201cspecial populations","volume":"38","author":"Pol","year":"2018","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.10.024_bib99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12916-017-0815-7","article-title":"Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals","volume":"15","author":"Baumert","year":"2017","journal-title":"BMC Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/vaccines4030027","article-title":"Highly-immunogenic\u00a0virally-vectored t-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection","volume":"4","author":"Swadling","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1053\/j.gastro.2018.10.024_bib101","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jvh.12632","article-title":"Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: a proof-of-concept study","volume":"24","author":"Smith","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.10.024_bib102","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(16)00120-1","article-title":"New perspectives for preventing hepatitis C virus liver graft infection","volume":"16","author":"Felmlee","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib103","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818759483","article-title":"Host-targeting therapies for hepatitis C virus infection: current developments and future applications","volume":"11","author":"Crouchet","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2018.10.024_bib104","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.chom.2014.10.009","article-title":"The impact of hepatitis C virus entry on viral tropism","volume":"16","author":"Ding","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1053\/j.gastro.2018.10.024_bib105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/infdis\/jit503","article-title":"Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study","volume":"209","author":"Sulkowski","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib106","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.3179","article-title":"Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody","volume":"33","author":"Mailly","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.gastro.2018.10.024_bib107","first-page":"1866","article-title":"Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking","volume":"15","author":"Blaising","year":"2013","journal-title":"Cell Microbiol"},{"key":"10.1053\/j.gastro.2018.10.024_bib108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"Xiao","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.10.024_bib109","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1021\/acsinfecdis.7b00091","article-title":"Entry inhibitors: a perspective for prevention of hepatitis C virus infection in organ transplantation","volume":"3","author":"Colpitts","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1053\/j.gastro.2018.10.024_bib110","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.10.024_bib111","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1073\/pnas.1016606108","article-title":"MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced by host RNA insertion or mutations in the HCV 5\u2032\u2019 UTR","volume":"108","author":"Li","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2018.10.024_bib113","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In\u00a0vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2018.10.024_bib112","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib114","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","article-title":"Safety, tolerability, and antiviral effect of RG-101 in patients\u00a0with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial","volume":"389","author":"Ree MH van der","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2018.10.024_bib115","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1172\/JCI63455","article-title":"MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis","volume":"122","author":"Tsai","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2018.10.024_bib116","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1053\/j.gastro.2018.10.024_bib117","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2014.07.008","article-title":"Cyclophilin inhibition as potential therapy for liver diseases","volume":"61","author":"Naoumov","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.10.024_bib118","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.10.024_bib119","doi-asserted-by":"crossref","first-page":"282ra49","DOI":"10.1126\/scitranslmed.3010286","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2018.10.024_bib120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0140-6736(17)30043-0","article-title":"Clinical development of hepatitis C virus host-targeting agents","volume":"389","author":"Zeisel","year":"2017","journal-title":"Lancet"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518351552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518351552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:45:24Z","timestamp":1762163124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508518351552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0016508518351552"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.10.024","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}